Stem cell therapy - ExCellThera

Drug Profile

Stem cell therapy - ExCellThera

Alternative Names: ECT-100; UM 171

Latest Information Update: 30 Dec 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator ExCellThera
  • Class Gene therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Acute myeloid leukaemia
  • Research Haemoglobinopathies

Most Recent Events

  • 21 Dec 2015 Early research in Haemoglobinopathies in Canada (Parenteral)
  • 21 Dec 2015 Health Canada approves IND application for ECT 100 in Acute myeloid leukaemia
  • 01 Dec 2015 Preclinical trials in Acute myeloid leukaemia in Canada (Parenteral) before December 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top